Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation and is a major cause of morbidity and mortality. While systemic corticosteroids are traditional first-line treatment for aGVHD, about half of patients are refractory to therapy. So what options are available for the treatment of steroid-refractory aGVHD? Join Doris Ponce, MD, and Corey Cutler, MD, MPH, for this podcast as they discuss different novel therapeutic options for managing aGVHD refractory to steroids.
This activity is jointly provided by Global Education Group and Spire Learning.
This activity is supported by an educational grant from CSL Behring LLC and Incyte Corporation.
Click here to listen to this podcast: